AMOR 1
Alternative Names: AMOR-1; Amorphous calcium carbonate (ACC) - Amorphical; Nanoparticulate amorphous calcium carbonate - AmorphicalLatest Information Update: 03 Dec 2025
At a glance
- Originator Amorphical
- Class Anti-inflammatories; Antineoplastics; Osteoporosis therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Yes - Hypoparathyroidism
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Hypoparathyroidism
- Phase II Pancreatic cancer
- Clinical Phase Unknown Crohn's disease; Osteoporosis
Most Recent Events
- 24 Nov 2025 Phase-II clinical trials in Pancreatic cancer (Late-stage disease) in Israel (PO) prior to September 2025
- 24 Nov 2025 The Helsinki Committee of Shaare Zedek Medical Center and the Israel Ministry of Health approves a phase II trial for AMOR 1 in Pancreatic cancer
- 30 Sep 2025 Clinical trials in Crohn's disease (Adjunctive treatment) in Israel (PO) prior to September 2025